Geron Corporation [NASDAQ: GERN] gained 2.82% on the last trading session, reaching $1.82 price per share at the time. The company report on August 6, 2020 that Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. The Company will host a conference call today at 4:30 p.m. ET to discuss second quarter financial results and current events.
“In the second quarter, we achieved a number of key milestones that have changed the trajectory of the Company,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “After a successful meeting with the FDA, we announced plans to move forward with a Phase 3 clinical trial in refractory MF with overall survival as the primary endpoint. This decision was based on overall survival data from the IMbark Phase 2 trial that suggest imetelstat treatment could potentially double the remaining life expectancy for patients who have become refractory to JAK inhibitors.”.
Geron Corporation represents 310.47 million in outstanding shares, while the company has a total market value of $575.41 million with the latest information. GERN stock price has been found in the range of $1.72 to $1.86.
If compared to the average trading volume of 3.66M shares, GERN reached a trading volume of 2683911 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Geron Corporation [GERN]:
Stifel have made an estimate for Geron Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 03, 2020. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on November 19, 2019, representing the official price target for Geron Corporation stock. Previously, the target price had yet another raise to $4, while H.C. Wainwright analysts kept a Buy rating on GERN stock.
The Average True Range (ATR) for Geron Corporation is set at 0.10, with the Price to Sales ratio for GERN stock in the period of the last 12 months amounting to 1438.53. The Price to Book ratio for the last quarter was 1.78, with the Price to Cash per share for the same quarter was set at 0.69.
Trading performance analysis for GERN stock
Geron Corporation [GERN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.75. With this latest performance, GERN shares dropped by -9.00% in over the last four-week period, additionally plugging by 40.00% over the last 6 months – not to mention a rise of 29.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GERN stock in for the last two-week period is set at 53.59, with the RSI for the last a single of trading hit 59.51, and the three-weeks RSI is set at 51.88 for Geron Corporation [GERN]. The present Moving Average for the last 50 days of trading for this stock 1.8715, while it was recorded at 1.7080 for the last single week of trading, and 1.4626 for the last 200 days.
Geron Corporation [GERN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Geron Corporation [GERN] shares currently have an operating margin of -15761.96. Geron Corporation’s Net Margin is presently recorded at -14901.74.
Return on Total Capital for GERN is now -45.97, given the latest momentum, and Return on Invested Capital for the company is -43.51. Return on Equity for this stock declined to -43.82, with Return on Assets sitting at -39.08. When it comes to the capital structure of this company, Geron Corporation [GERN] has a Total Debt to Total Equity ratio set at 1.89. Additionally, GERN Total Debt to Total Capital is recorded at 1.85, with Total Debt to Total Assets ending up at 1.54. Long-Term Debt to Equity for the company is recorded at 1.63, with the Long-Term Debt to Total Capital now at 1.60.
Reflecting on the efficiency of the workforce at the company, Geron Corporation [GERN] managed to generate an average of -$1,490,174 per employee. Receivables Turnover for the company is 0.47 with a Total Asset Turnover recorded at a value of 0.00.Geron Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.50 and a Current Ratio set at 11.50.
Geron Corporation [GERN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Geron Corporation posted -0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.15/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 46.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GERN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Geron Corporation go to 5.00%.
An analysis of insider ownership at Geron Corporation [GERN]
There are presently around $257 million, or 38.90% of GERN stock, in the hands of institutional investors. The top three institutional holders of GERN stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 30,126,299, which is approximately New of the company’s market cap and around 0.41% of the total institutional ownership; BLACKROCK INC., holding 19,400,364 shares of the stock with an approximate value of $35.31 million in GERN stocks shares; and ECOR1 CAPITAL, LLC, currently with $35.0 million in GERN stock with ownership of nearly New of the company’s market capitalization.
Positions in Geron Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 78 institutional holders increased their position in Geron Corporation [NASDAQ:GERN] by around 82,014,688 shares. Additionally, 30 investors decreased positions by around 2,423,058 shares, while 41 investors held positions by with 56,682,498 shares. The mentioned changes placed institutional holdings at 141,120,244 shares, according to the latest SEC report filing. GERN stock had 32 new institutional investments in for a total of 67,233,094 shares, while 8 institutional investors sold positions of 582,523 shares during the same period.